PortfoliosLab logoPortfoliosLab logo
ISIN
US64131A1051
CUSIP
64131A105
IPO Date
Jun 28, 2018

Highlights

Market Cap
$108.56M
Enterprise Value
$124.86M
EPS (TTM)
-$0.55
Total Revenue (TTM)
$151.64M
Gross Profit (TTM)
$72.72M
EBITDA (TTM)
-$27.11M
Year Range
$0.80 - $4.85
Target Price
$8.00
ROA (TTM)
-29.59%
ROE (TTM)
-279.78%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Neuronetics, Inc.

Performance

STIM Performance Chart

Neuronetics, Inc. (STIM) is up 13.0% since the beginning of the year. At $2 per share, STIM is trading 67.8% below its 52-week high of $5. Investors who bought $1,000 worth of STIM shares 5 years ago would now be looking at an investment worth $113.


Loading charts...

S&P 500 Index

Returns By Period

Neuronetics, Inc. (STIM) has returned 13.04% so far this year and -59.06% over the past 12 months.


Neuronetics, Inc.

1D
-6.59%
1M
-22.77%
YTD
13.04%
6M
18.18%
1Y
-59.06%
3Y*
-16.81%
5Y*
-35.33%
10Y*

Benchmark (S&P 500 Index)

1D
0.13%
1M
5.25%
YTD
11.16%
6M
11.43%
1Y
28.20%
3Y*
21.12%
5Y*
12.66%
10Y*
13.75%
*Multi-year figures are annualized to reflect compound growth (CAGR)

STIM Monthly Returns History

Based on dividend-adjusted daily data since Jun 28, 2018, STIM's average daily return is +0.04%, while the average monthly return is +1.60%. At this rate, an investment would double in approximately 3.6 years.

Historically, 41% of months were positive and 59% were negative. The best month was Aug 2020 with a return of +119.9%, while the worst month was Aug 2024 at -52.8%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.

On a daily basis, STIM closed higher 46% of trading days. The best single day was May 4, 2021 with a return of +39.2%, while the worst single day was Aug 12, 2024 at -58.2%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202651.45%-35.89%8.21%33.79%-20.62%1.30%13.04%
202592.55%37.10%-13.41%19.02%-10.73%-10.74%25.79%-24.15%-18.02%-2.93%-43.77%-7.38%-14.29%
202417.24%-11.76%58.67%-29.20%-43.03%-6.25%3.89%-52.78%-13.96%35.56%-2.91%61.00%-44.48%
2023-14.41%-3.23%-48.86%-21.31%19.21%-21.25%-8.37%-16.75%-17.68%-14.81%58.26%59.34%-57.79%
2022-19.73%-6.70%-9.28%-19.47%9.84%19.78%29.91%-14.39%-10.92%4.72%88.59%9.39%54.04%
202158.69%-11.91%-20.35%-15.12%29.24%18.05%-17.23%-49.32%-2.38%-20.73%-25.58%15.25%-59.86%

Benchmark Metrics

Neuronetics, Inc. has an annualized alpha of -9.00%, beta of 1.34, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since June 29, 2018.

  • This stock participated in 138.53% of S&P 500 Index downside but only -18.89% of its upside - more exposed to losses than it benefited from rallies.
  • R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-9.00%
Beta
1.34
0.07
Upside Capture
-18.89%
Downside Capture
138.53%

Return for Risk

Risk / Return Rank

STIM ranks 16 for risk / return — in the bottom 16% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.


STIM Risk / Return Rank: 1616
Overall Rank
STIM Sharpe Ratio Rank: 1515
Sharpe Ratio Rank
STIM Sortino Ratio Rank: 1717
Sortino Ratio Rank
STIM Omega Ratio Rank: 1919
Omega Ratio Rank
STIM Calmar Ratio Rank: 1010
Calmar Ratio Rank
STIM Martin Ratio Rank: 1717
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Neuronetics, Inc. (STIM) and compare them to S&P 500 Index.


STIMBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

-0.59

2.39

-2.98

Sortino ratio

Return per unit of downside risk

-0.61

3.25

-3.86

Omega ratio

Gain probability vs. loss probability

0.93

1.43

-0.50

Calmar ratio

Return relative to maximum drawdown

-0.79

3.11

-3.91

Martin ratio

Return relative to average drawdown

-1.11

14.38

-15.49

Dividends

Dividend History


Neuronetics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Neuronetics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Neuronetics, Inc. was 98.38%, occurring on Nov 13, 2024. The portfolio has not yet recovered.

The current Neuronetics, Inc. drawdown is 95.84%.


Related event

Drawdown

Fall

Recovery

Underwater

2024 bear market2024
-98.38%Nov 2024
6y 2mo
7y 8moSep 2018 - now
2018 correction2018
-12.46%Aug 2018
1mo 4d6d
1mo 10dJun 2018 - Aug 2018
2018 pullback2018
-6.68%Aug 2018
4d5d
9dAug 2018 - Aug 2018
2018 pullback2018
-3.34%Aug 2018
5d1d
6dAug 2018 - Aug 2018
2018 pullback2018
-2.39%Aug 2018
1d5d
6dAug 2018 - Sep 2018

Drawdown Indicators


STIMBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-98.38%

-56.78%

-41.60%

Max Drawdown (1Y)

Largest decline over 1 year

-74.68%

-9.10%

-65.58%

Max Drawdown (3Y)

Largest decline over 3 years

-87.33%

-18.90%

-68.43%

Max Drawdown (5Y)

Largest decline over 5 years

-96.47%

-25.43%

-71.04%

Max Drawdown (10Y)

Largest decline over 10 years

-33.92%

Current Drawdown

Current decline from peak

-95.84%

0.00%

-95.84%

Average Drawdown

Average peak-to-trough decline

-81.86%

-10.72%

-71.14%

Ulcer Index

Depth and duration of drawdowns from previous peaks

53.13%

1.97%

+51.16%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Neuronetics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Neuronetics, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for STIM relative to other companies in the Diagnostics & Research industry. Currently, STIM has a P/S ratio of 0.7. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for STIM in comparison with other companies in the Diagnostics & Research industry. Currently, STIM has a P/B value of 8.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with STIM

Add Neuronetics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with STIM